

Antitussive Drugs Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Drug Class (Peripherally Acting Drugs, Centrally Acting Drugs, Others), By Route of Administration (Inhalational, Oral, Others), By Age Group (Geriatric, Pediatric, Adult), By End-User (Homecare, Hospitals & Specialty Clinics, Others), By Region & Competition, 2020-2030F

https://marketpublishers.com/r/A59A869D1DB8EN.html

Date: April 2025 Pages: 180 Price: US\$ 4,500.00 (Single User License) ID: A59A869D1DB8EN

Abstracts

Global Antitussive Drugs Market was valued at USD 1.60 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 5.20% through 2030. The Global Antitussive Drugs Market is experiencing sustained growth, primarily driven by the rising prevalence of respiratory diseases, an expanding elderly population, and improved healthcare accessibility. Antitussive drugs, or cough suppressants, are essential in managing acute and chronic coughs linked to conditions such as upper respiratory tract infections (URTIs), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, and post-viral syndromes.

This market benefits from strong consumer demand for both over-the-counter (OTC) and prescription-based antitussive medications, with major contributions from leading pharmaceutical corporations and emerging industry players. Ongoing research and development (R&D) efforts, alongside advancements in drug formulations, are shaping competitive dynamics and fostering product innovation.

Key Market Drivers



Rising Prevalence of Respiratory Diseases

The rising prevalence of respiratory diseases is one of the most significant drivers fueling the expansion of the Global Antitussive Drugs Market. With an increasing number of people experiencing respiratory illnesses, the demand for cough suppressants and related medications is witnessing steady growth. Each year, chronic obstructive pulmonary disease (COPD) claims over 3 million lives, yet it remains significantly underprioritized in global healthcare discussions. Affecting more than 380 million people worldwide, COPD is the fourth leading cause of death, imposing a severe economic and healthcare burden. Despite its widespread impact on patients, caregivers, and healthcare systems, the disease continues to receive disproportionately low attention and funding compared to other major noncommunicable diseases. Chronic and acute respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, bronchitis, pneumonia, tuberculosis (TB), and post-viral cough syndromes, are becoming more prevalent worldwide. In 2023, tuberculosis (TB) affected an estimated 10.8 million people globally, including 6.0 million men, 3.6 million women, and 1.3 million children, highlighting its widespread impact across demographics. Present in every country and affecting all age groups, TB continues to pose a significant public health challenge. These conditions often manifest with persistent coughing, requiring effective antitussive (cough suppressant) treatments.

Key Market Challenges

Regulatory Hurdles and Stringent Approvals

One of the primary challenges in the antitussive drugs market is the rigorous regulatory environment governing pharmaceuticals. To ensure safety and efficacy, regulatory agencies such as the FDA (U.S. Food and Drug Administration) and the EMA (European Medicines Agency) impose stringent approval processes for new antitussive drugs.

Developing and bringing a new antitussive drug to market involves extensive clinical trials, data submission, and regulatory reviews. The process is time-consuming and costly, with no guarantee of approval. Companies may face delays, increased development costs, or even the rejection of their drug candidates, impacting market entry.

Key Market Trends



Shift Towards Non-Opioid and Non-Codeine Formulations

One of the prominent trends in the antitussive drugs market is the increasing preference for non-opioid and non-codeine formulations. This shift is primarily driven by concerns related to the addictive potential and side effects associated with opioid-based antitussive drugs.

Regulatory Scrutiny: Regulatory agencies like the FDA have imposed stricter controls and monitoring of opioid-based medications due to their potential for abuse and addiction. This has led to a reduced appetite among healthcare providers to prescribe such drugs. Patient Safety: Patient safety and minimizing the risk of opioid misuse have become paramount concerns. Non-opioid alternatives are seen as safer options for managing coughing, especially in pediatric and vulnerable patient populations.

Advances in pharmaceutical research have led to the development of non-opioid antitussive medications that offer comparable efficacy in suppressing coughing without the risk of opioid-related complications. This has fueled the market demand for nonopioid alternatives.

Key Market Players

Teva Pharmaceutical Industries Ltd.

Intas Pharmaceuticals Ltd.

Bayer AG

Ipca Laboratories Ltd.

F. Hoffmann-La Roche Ltd.

Hikma Pharmaceuticals PLC

Unique Pharmaceuticals Limited

Cipla Inc.

Viatris Inc.



Aurobindo Pharma

Report Scope:

In this report, the Global Antitussive Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antitussive Drugs Market, By Drug Class:	

Peripherally Acting Drugs

Centrally Acting Drugs

Others

Antitussive Drugs Market, By Route of Administration:

Inhalational

Oral

Others

Antitussive Drugs Market, By Age Group:

Geriatric

Pediatric

Adult

Antitussive Drugs Market, By End-User:

Homecare

Hospitals & Specialty Clinics



Others

Antitussive Drugs Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil



Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antitussive Drugs Market.

Available Customizations:

Global Antitussive Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).



Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. ANTITUSSIVE DRUGS MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Drug Class (Peripherally Acting Drugs, Centrally Acting Drugs, Others)
 - 5.2.2. By Route of Administration (Inhalational, Oral, Others)
- 5.2.3. By Age Group (Geriatric, Pediatric, Adult)
- 5.2.4. By End-User (Homecare, Hospitals & Specialty Clinics, Others)



5.2.5. By Region5.2.6. By Company (2024)5.3. Market Map

6. NORTH AMERICA ANTITUSSIVE DRUGS MARKET OUTLOOK

- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Drug Class
- 6.2.2. By Route of Administration
- 6.2.3. By Age Group
- 6.2.4. By End User
- 6.2.5. By Country
- 6.3. North America: Country Analysis
 - 6.3.1. United States Antitussive Drugs Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Drug Class
 - 6.3.1.2.2. By Route of Administration
 - 6.3.1.2.3. By Age Group
 - 6.3.1.2.4. By End User
 - 6.3.2. Canada Antitussive Drugs Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Drug Class
 - 6.3.2.2.2. By Route of Administration
 - 6.3.2.2.3. By Age Group
 - 6.3.2.2.4. By End User
 - 6.3.3. Mexico Antitussive Drugs Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Drug Class
 - 6.3.3.2.2. By Route of Administration
 - 6.3.3.2.3. By Age Group
 - 6.3.3.2.4. By End User



7. EUROPE ANTITUSSIVE DRUGS MARKET OUTLOOK

- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Drug Class
 - 7.2.2. By Route of Administration
 - 7.2.3. By Age Group
 - 7.2.4. By End User
 - 7.2.5. By Country
- 7.3. Europe: Country Analysis
 - 7.3.1. Germany Antitussive Drugs Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Drug Class
 - 7.3.1.2.2. By Route of Administration
 - 7.3.1.2.3. By Age Group
 - 7.3.1.2.4. By End User
 - 7.3.2. United Kingdom Antitussive Drugs Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Drug Class
 - 7.3.2.2.2. By Route of Administration
 - 7.3.2.2.3. By Age Group
 - 7.3.2.2.4. By End User
 - 7.3.3. Italy Antitussive Drugs Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Drug Class
 - 7.3.3.2.2. By Route of Administration
 - 7.3.3.2.3. By Age Group
 - 7.3.3.2.4. By End User
 - 7.3.4. France Antitussive Drugs Market Outlook
 - 7.3.4.1. Market Size & Forecast
 - 7.3.4.1.1. By Value



- 7.3.4.2. Market Share & Forecast
 - 7.3.4.2.1. By Drug Class
 - 7.3.4.2.2. By Route of Administration
 - 7.3.4.2.3. By Age Group
 - 7.3.4.2.4. By End User
- 7.3.5. Spain Antitussive Drugs Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value
 - 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Drug Class
 - 7.3.5.2.2. By Route of Administration
 - 7.3.5.2.3. By Age Group
 - 7.3.5.2.4. By End User

8. ASIA-PACIFIC ANTITUSSIVE DRUGS MARKET OUTLOOK

- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Drug Class
 - 8.2.2. By Route of Administration
 - 8.2.3. By Age Group
 - 8.2.4. By End User
 - 8.2.5. By Country
- 8.3. Asia-Pacific: Country Analysis
 - 8.3.1. China Antitussive Drugs Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Drug Class
 - 8.3.1.2.2. By Route of Administration
 - 8.3.1.2.3. By Age Group
 - 8.3.1.2.4. By End User
 - 8.3.2. India Antitussive Drugs Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Drug Class
 - 8.3.2.2.2. By Route of Administration



- 8.3.2.2.3. By Age Group
- 8.3.2.2.4. By End User
- 8.3.3. Japan Antitussive Drugs Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Drug Class
 - 8.3.3.2.2. By Route of Administration
 - 8.3.3.2.3. By Age Group
 - 8.3.3.2.4. By End User
- 8.3.4. South Korea Antitussive Drugs Market Outlook
 - 8.3.4.1. Market Size & Forecast
 - 8.3.4.1.1. By Value
 - 8.3.4.2. Market Share & Forecast
 - 8.3.4.2.1. By Drug Class
 - 8.3.4.2.2. By Route of Administration
 - 8.3.4.2.3. By Age Group
 - 8.3.4.2.4. By End User
- 8.3.5. Australia Antitussive Drugs Market Outlook
 - 8.3.5.1. Market Size & Forecast
 - 8.3.5.1.1. By Value
 - 8.3.5.2. Market Share & Forecast
 - 8.3.5.2.1. By Drug Class
 - 8.3.5.2.2. By Route of Administration
 - 8.3.5.2.3. By Age Group
 - 8.3.5.2.4. By End User

9. SOUTH AMERICA ANTITUSSIVE DRUGS MARKET OUTLOOK

- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Drug Class
 - 9.2.2. By Route of Administration
 - 9.2.3. By Age Group
 - 9.2.4. By End User
 - 9.2.5. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Antitussive Drugs Market Outlook



- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Drug Class
- 9.3.1.2.2. By Route of Administration
- 9.3.1.2.3. By Age Group
- 9.3.1.2.4. By End User
- 9.3.2. Argentina Antitussive Drugs Market Outlook
- 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Drug Class
- 9.3.2.2.2. By Route of Administration
- 9.3.2.2.3. By Age Group
- 9.3.2.2.4. By End User
- 9.3.3. Colombia Antitussive Drugs Market Outlook
- 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Drug Class
- 9.3.3.2.2. By Route of Administration
- 9.3.3.2.3. By Age Group
- 9.3.3.2.4. By End User

10. MIDDLE EAST AND AFRICA ANTITUSSIVE DRUGS MARKET OUTLOOK

- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Drug Class
 - 10.2.2. By Route of Administration
 - 10.2.3. By Age Group
 - 10.2.4. By End User
- 10.2.5. By Country
- 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Antitussive Drugs Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast



- 10.3.1.2.1. By Drug Class
- 10.3.1.2.2. By Route of Administration
- 10.3.1.2.3. By Age Group
- 10.3.1.2.4. By End User
- 10.3.2. Saudi Arabia Antitussive Drugs Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value
 - 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Drug Class
 - 10.3.2.2.2. By Route of Administration
 - 10.3.2.2.3. By Age Group
 - 10.3.2.2.4. By End User
- 10.3.3. UAE Antitussive Drugs Market Outlook
- 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Drug Class
 - 10.3.3.2.2. By Route of Administration
 - 10.3.3.2.3. By Age Group
 - 10.3.3.2.4. By End User

11. MARKET DYNAMICS

- 11.1. Drivers
- 11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions

13. GLOBAL ANTITUSSIVE DRUGS MARKET: SWOT ANALYSIS

14. COMPETITIVE LANDSCAPE

- 14.1. Teva Pharmaceutical Industries Ltd.
 - 14.1.1. Business Overview
 - 14.1.2. Product & Service Offerings



- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
- 14.2. Intas Pharmaceuticals Ltd.
- 14.3. Bayer AG
- 14.4. Ipca Laboratories Ltd.
- 14.5. F. Hoffmann-La Roche Ltd.
- 14.6. Hikma Pharmaceuticals PLC
- 14.7. Unique Pharmaceuticals Limited
- 14.8. Cipla Inc.
- 14.9. Viatris Inc.
- 14.10. Aurobindo Pharma

15. STRATEGIC RECOMMENDATIONS

16. ABOUT US & DISCLAIMER



I would like to order

Product name: Antitussive Drugs Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Drug Class (Peripherally Acting Drugs, Centrally Acting Drugs, Others), By Route of Administration (Inhalational, Oral, Others), By Age Group (Geriatric, Pediatric, Adult), By End-User (Homecare, Hospitals & Specialty Clinics, Others), By Region & Competition, 2020-2030F

Product link: https://marketpublishers.com/r/A59A869D1DB8EN.html

Price: US\$ 4,500.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/A59A869D1DB8EN.html</u>